| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 233 | 2024 | 11039 | 10.280 |
Why?
|
| Prostatectomy | 72 | 2023 | 1871 | 6.160 |
Why?
|
| Urinary Bladder Neoplasms | 73 | 2023 | 2229 | 5.540 |
Why?
|
| Cystectomy | 49 | 2022 | 682 | 4.910 |
Why?
|
| Prostate-Specific Antigen | 57 | 2024 | 2458 | 3.500 |
Why?
|
| Prostate | 31 | 2024 | 1764 | 2.710 |
Why?
|
| Androgen Antagonists | 26 | 2023 | 1350 | 2.340 |
Why?
|
| Kidney Neoplasms | 34 | 2023 | 4229 | 2.210 |
Why?
|
| Carcinoma, Transitional Cell | 13 | 2021 | 798 | 1.860 |
Why?
|
| Nephrectomy | 25 | 2022 | 1049 | 1.740 |
Why?
|
| Genetic Predisposition to Disease | 44 | 2023 | 17400 | 1.380 |
Why?
|
| Male | 366 | 2024 | 349538 | 1.340 |
Why?
|
| Laparoscopy | 23 | 2023 | 2121 | 1.310 |
Why?
|
| Carcinoma, Renal Cell | 21 | 2023 | 3123 | 1.260 |
Why?
|
| Antineoplastic Agents, Hormonal | 12 | 2023 | 1509 | 1.180 |
Why?
|
| Neoplasm Staging | 44 | 2022 | 11001 | 1.160 |
Why?
|
| Polymorphism, Single Nucleotide | 43 | 2023 | 15494 | 1.110 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2018 | 414 | 1.090 |
Why?
|
| Phenylthiohydantoin | 5 | 2021 | 192 | 1.050 |
Why?
|
| Robotics | 15 | 2023 | 892 | 1.010 |
Why?
|
| Aged | 209 | 2023 | 162944 | 0.980 |
Why?
|
| Humans | 403 | 2024 | 742088 | 0.950 |
Why?
|
| Orchiectomy | 6 | 2016 | 466 | 0.930 |
Why?
|
| Early Detection of Cancer | 20 | 2024 | 3070 | 0.930 |
Why?
|
| Postoperative Complications | 43 | 2023 | 15244 | 0.920 |
Why?
|
| Kallikreins | 10 | 2021 | 258 | 0.910 |
Why?
|
| Lymph Node Excision | 15 | 2019 | 1248 | 0.860 |
Why?
|
| Middle Aged | 195 | 2023 | 213127 | 0.840 |
Why?
|
| Biopsy | 11 | 2024 | 6756 | 0.820 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2021 | 29 | 0.810 |
Why?
|
| Urologic Neoplasms | 6 | 2017 | 316 | 0.790 |
Why?
|
| Ureteral Neoplasms | 2 | 2021 | 110 | 0.770 |
Why?
|
| SEER Program | 15 | 2023 | 1507 | 0.760 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2020 | 39 | 0.730 |
Why?
|
| Brachytherapy | 7 | 2018 | 1246 | 0.730 |
Why?
|
| Neoadjuvant Therapy | 14 | 2023 | 2721 | 0.730 |
Why?
|
| DNA Repair | 6 | 2023 | 2042 | 0.720 |
Why?
|
| Neoplasm Recurrence, Local | 19 | 2023 | 9185 | 0.720 |
Why?
|
| Receptors, Androgen | 8 | 2021 | 1057 | 0.700 |
Why?
|
| Urology | 5 | 2020 | 397 | 0.690 |
Why?
|
| Multifactorial Inheritance | 7 | 2023 | 1190 | 0.640 |
Why?
|
| Tissue Extracts | 4 | 2022 | 135 | 0.630 |
Why?
|
| Germ-Line Mutation | 8 | 2022 | 1786 | 0.620 |
Why?
|
| Healthcare Disparities | 11 | 2023 | 3151 | 0.610 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2014 | 113 | 0.570 |
Why?
|
| Polymorphism, Genetic | 5 | 2016 | 4328 | 0.570 |
Why?
|
| Poultry | 1 | 2016 | 82 | 0.570 |
Why?
|
| Cancer Vaccines | 2 | 2022 | 1021 | 0.570 |
Why?
|
| Urothelium | 3 | 2017 | 277 | 0.560 |
Why?
|
| Chromosomes, Human, Pair 12 | 4 | 2004 | 462 | 0.560 |
Why?
|
| Urogenital Neoplasms | 2 | 2009 | 135 | 0.560 |
Why?
|
| Medical Oncology | 6 | 2020 | 2235 | 0.550 |
Why?
|
| Disease Management | 3 | 2017 | 2450 | 0.540 |
Why?
|
| United States | 84 | 2024 | 69693 | 0.540 |
Why?
|
| Genome-Wide Association Study | 30 | 2023 | 12220 | 0.540 |
Why?
|
| Carcinoma | 7 | 2010 | 2374 | 0.540 |
Why?
|
| Cell Cycle Proteins | 5 | 2016 | 3444 | 0.520 |
Why?
|
| Leuprolide | 5 | 2021 | 303 | 0.520 |
Why?
|
| Eggs | 1 | 2016 | 184 | 0.520 |
Why?
|
| Treatment Outcome | 66 | 2023 | 62966 | 0.510 |
Why?
|
| Watchful Waiting | 5 | 2023 | 491 | 0.510 |
Why?
|
| Risk Assessment | 41 | 2022 | 23320 | 0.500 |
Why?
|
| Retrospective Studies | 78 | 2023 | 77098 | 0.500 |
Why?
|
| Aged, 80 and over | 64 | 2022 | 57683 | 0.500 |
Why?
|
| DNA, Neoplasm | 3 | 2013 | 1758 | 0.500 |
Why?
|
| Lymphatic Metastasis | 9 | 2019 | 2906 | 0.490 |
Why?
|
| Nomograms | 3 | 2014 | 224 | 0.480 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2015 | 315 | 0.480 |
Why?
|
| Risk Factors | 63 | 2023 | 72145 | 0.480 |
Why?
|
| Tumor Burden | 4 | 2019 | 1905 | 0.470 |
Why?
|
| BCG Vaccine | 3 | 2023 | 367 | 0.470 |
Why?
|
| Chromosome Deletion | 3 | 2004 | 1400 | 0.460 |
Why?
|
| Fishes | 1 | 2016 | 569 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2020 | 11472 | 0.450 |
Why?
|
| Chromosome Mapping | 10 | 2018 | 4742 | 0.440 |
Why?
|
| Mandelic Acids | 1 | 2012 | 47 | 0.440 |
Why?
|
| Survival Rate | 24 | 2021 | 12773 | 0.440 |
Why?
|
| Chemotherapy, Adjuvant | 17 | 2020 | 3471 | 0.430 |
Why?
|
| Urologic Surgical Procedures | 4 | 2016 | 301 | 0.420 |
Why?
|
| Venous Thromboembolism | 6 | 2020 | 1668 | 0.420 |
Why?
|
| Neoplasm Invasiveness | 15 | 2021 | 3612 | 0.420 |
Why?
|
| Muscarinic Antagonists | 1 | 2012 | 137 | 0.410 |
Why?
|
| Surgery, Computer-Assisted | 4 | 2013 | 1009 | 0.410 |
Why?
|
| Urinary Incontinence | 3 | 2021 | 494 | 0.400 |
Why?
|
| Genetic Loci | 7 | 2021 | 2572 | 0.400 |
Why?
|
| MicroRNAs | 6 | 2020 | 3731 | 0.400 |
Why?
|
| Hospitals | 10 | 2022 | 3937 | 0.400 |
Why?
|
| Androgens | 7 | 2023 | 1271 | 0.400 |
Why?
|
| Erectile Dysfunction | 4 | 2023 | 459 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2021 | 462 | 0.390 |
Why?
|
| Medicare | 11 | 2023 | 6532 | 0.380 |
Why?
|
| Urinary Diversion | 3 | 2017 | 137 | 0.380 |
Why?
|
| Lung Diseases | 2 | 2020 | 1884 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2019 | 6534 | 0.380 |
Why?
|
| Antineoplastic Agents | 9 | 2023 | 13655 | 0.380 |
Why?
|
| Prognosis | 33 | 2021 | 29010 | 0.380 |
Why?
|
| Adenocarcinoma | 8 | 2019 | 6347 | 0.380 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2016 | 2842 | 0.370 |
Why?
|
| Pelvic Neoplasms | 2 | 2020 | 254 | 0.370 |
Why?
|
| Genes, cdc | 2 | 2008 | 116 | 0.370 |
Why?
|
| Patient Readmission | 12 | 2019 | 3111 | 0.370 |
Why?
|
| Testicular Neoplasms | 5 | 2016 | 761 | 0.360 |
Why?
|
| Proportional Hazards Models | 21 | 2021 | 12344 | 0.360 |
Why?
|
| Caspase 8 | 1 | 2010 | 195 | 0.350 |
Why?
|
| Disease-Free Survival | 16 | 2022 | 6891 | 0.350 |
Why?
|
| Length of Stay | 19 | 2020 | 6294 | 0.350 |
Why?
|
| Prospective Studies | 40 | 2023 | 53187 | 0.350 |
Why?
|
| Adult | 79 | 2023 | 213712 | 0.340 |
Why?
|
| Taxoids | 4 | 2017 | 665 | 0.330 |
Why?
|
| Genotype | 21 | 2021 | 12946 | 0.330 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 1640 | 0.330 |
Why?
|
| Androstenes | 2 | 2021 | 169 | 0.330 |
Why?
|
| Case-Control Studies | 30 | 2022 | 21719 | 0.330 |
Why?
|
| Kidney Pelvis | 3 | 2019 | 188 | 0.320 |
Why?
|
| Databases, Factual | 22 | 2020 | 7716 | 0.320 |
Why?
|
| Female | 119 | 2023 | 379592 | 0.320 |
Why?
|
| Homeodomain Proteins | 3 | 2022 | 2417 | 0.310 |
Why?
|
| Salvage Therapy | 3 | 2023 | 1269 | 0.310 |
Why?
|
| Colectomy | 4 | 2020 | 681 | 0.310 |
Why?
|
| Muscle Neoplasms | 2 | 2019 | 139 | 0.300 |
Why?
|
| Neoplasm Metastasis | 11 | 2019 | 4839 | 0.300 |
Why?
|
| Vena Cava, Inferior | 2 | 2003 | 436 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2019 | 8425 | 0.300 |
Why?
|
| Adjuvants, Immunologic | 1 | 2012 | 1000 | 0.300 |
Why?
|
| Germ Cells | 5 | 2023 | 628 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3239 | 0.290 |
Why?
|
| Follow-Up Studies | 32 | 2022 | 39004 | 0.290 |
Why?
|
| Urinary Bladder | 8 | 2023 | 1171 | 0.290 |
Why?
|
| Health Expenditures | 7 | 2023 | 2346 | 0.290 |
Why?
|
| Genetic Variation | 10 | 2020 | 6540 | 0.290 |
Why?
|
| Health Care Costs | 6 | 2020 | 3203 | 0.290 |
Why?
|
| Cell Movement | 3 | 2018 | 5212 | 0.280 |
Why?
|
| Health Services Accessibility | 6 | 2023 | 5133 | 0.280 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2009 | 638 | 0.280 |
Why?
|
| Logistic Models | 17 | 2023 | 13403 | 0.270 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2019 | 441 | 0.270 |
Why?
|
| Immunotherapy | 5 | 2022 | 4414 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2017 | 199 | 0.270 |
Why?
|
| Clinical Medicine | 1 | 2007 | 147 | 0.270 |
Why?
|
| Mass Screening | 9 | 2024 | 5238 | 0.270 |
Why?
|
| Genes, BRCA2 | 5 | 2023 | 617 | 0.270 |
Why?
|
| Survival Analysis | 17 | 2021 | 10248 | 0.260 |
Why?
|
| Nitriles | 5 | 2021 | 952 | 0.260 |
Why?
|
| Inheritance Patterns | 2 | 2019 | 340 | 0.260 |
Why?
|
| Incidence | 22 | 2023 | 20928 | 0.260 |
Why?
|
| Hysterectomy | 3 | 2020 | 927 | 0.260 |
Why?
|
| Hospital Costs | 6 | 2022 | 980 | 0.260 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 1780 | 0.250 |
Why?
|
| Postoperative Care | 1 | 2011 | 1484 | 0.250 |
Why?
|
| Age Factors | 13 | 2022 | 18355 | 0.250 |
Why?
|
| Combined Modality Therapy | 12 | 2021 | 8621 | 0.250 |
Why?
|
| Muscles | 5 | 2021 | 1617 | 0.250 |
Why?
|
| DNA-Binding Proteins | 4 | 2016 | 9639 | 0.250 |
Why?
|
| Multivariate Analysis | 16 | 2021 | 12242 | 0.240 |
Why?
|
| Urology Department, Hospital | 1 | 2003 | 1 | 0.240 |
Why?
|
| Loss of Heterozygosity | 3 | 2004 | 678 | 0.240 |
Why?
|
| Acute Kidney Injury | 4 | 2020 | 1967 | 0.240 |
Why?
|
| Surgical Procedures, Operative | 4 | 2016 | 1873 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 4553 | 0.230 |
Why?
|
| Time Factors | 26 | 2021 | 40054 | 0.230 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 484 | 0.230 |
Why?
|
| Hematuria | 1 | 2005 | 235 | 0.230 |
Why?
|
| Cyclins | 2 | 2003 | 601 | 0.230 |
Why?
|
| Odds Ratio | 14 | 2021 | 9846 | 0.230 |
Why?
|
| Calcium | 2 | 2015 | 5753 | 0.230 |
Why?
|
| Quality of Life | 12 | 2023 | 12730 | 0.230 |
Why?
|
| Hospitalization | 6 | 2019 | 10232 | 0.220 |
Why?
|
| Insurance, Health | 3 | 2020 | 2493 | 0.220 |
Why?
|
| Medicaid | 5 | 2023 | 2716 | 0.220 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2008 | 1097 | 0.220 |
Why?
|
| Ultrasonography, Interventional | 2 | 2008 | 1483 | 0.220 |
Why?
|
| Comparative Effectiveness Research | 5 | 2018 | 681 | 0.220 |
Why?
|
| Disease Progression | 11 | 2021 | 13256 | 0.220 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2004 | 168 | 0.220 |
Why?
|
| Prednisone | 3 | 2021 | 1567 | 0.210 |
Why?
|
| Mendelian Randomization Analysis | 6 | 2018 | 963 | 0.210 |
Why?
|
| Neoplasms | 10 | 2023 | 21596 | 0.210 |
Why?
|
| Registries | 7 | 2023 | 8077 | 0.210 |
Why?
|
| Laser Therapy | 2 | 2023 | 1071 | 0.210 |
Why?
|
| Benzamides | 4 | 2021 | 1378 | 0.210 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2001 | 933 | 0.210 |
Why?
|
| Genetic Testing | 2 | 2023 | 3439 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2023 | 1769 | 0.200 |
Why?
|
| Absenteeism | 2 | 2020 | 250 | 0.200 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2018 | 1185 | 0.200 |
Why?
|
| Gene Frequency | 5 | 2017 | 3587 | 0.200 |
Why?
|
| Blood Transfusion | 5 | 2020 | 1296 | 0.200 |
Why?
|
| Convalescence | 2 | 2020 | 105 | 0.200 |
Why?
|
| Cohort Studies | 21 | 2023 | 40450 | 0.200 |
Why?
|
| Hypercalcemia | 1 | 2004 | 405 | 0.200 |
Why?
|
| Thiohydantoins | 1 | 2021 | 20 | 0.200 |
Why?
|
| Germinoma | 1 | 2002 | 133 | 0.200 |
Why?
|
| Cryptorchidism | 1 | 2002 | 123 | 0.190 |
Why?
|
| Predictive Value of Tests | 12 | 2021 | 15056 | 0.190 |
Why?
|
| Peripheral Arterial Disease | 1 | 2012 | 1184 | 0.190 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2022 | 106 | 0.190 |
Why?
|
| Smoking | 6 | 2023 | 8969 | 0.190 |
Why?
|
| Antineoplastic Protocols | 1 | 2020 | 47 | 0.190 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 4187 | 0.190 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 14 | 0.190 |
Why?
|
| Prostatic Hyperplasia | 2 | 2015 | 522 | 0.190 |
Why?
|
| Access to Information | 1 | 2023 | 320 | 0.180 |
Why?
|
| Insurance Coverage | 3 | 2021 | 1895 | 0.180 |
Why?
|
| Patient Protection and Affordable Care Act | 5 | 2023 | 1208 | 0.180 |
Why?
|
| Ileus | 1 | 2020 | 58 | 0.180 |
Why?
|
| Ligases | 3 | 1997 | 332 | 0.180 |
Why?
|
| Rhabdomyolysis | 2 | 2015 | 150 | 0.180 |
Why?
|
| Thromboembolism | 2 | 1997 | 983 | 0.180 |
Why?
|
| Risk | 11 | 2018 | 9679 | 0.180 |
Why?
|
| X Chromosome | 1 | 2003 | 815 | 0.180 |
Why?
|
| Breast Neoplasms | 10 | 2022 | 20774 | 0.180 |
Why?
|
| Retroperitoneal Space | 2 | 2011 | 172 | 0.170 |
Why?
|
| Comorbidity | 8 | 2018 | 10372 | 0.170 |
Why?
|
| Motor Activity | 1 | 2009 | 2714 | 0.170 |
Why?
|
| Receptors, Calcitriol | 2 | 1999 | 350 | 0.170 |
Why?
|
| Diet | 2 | 2021 | 7923 | 0.170 |
Why?
|
| Urologic Diseases | 2 | 2007 | 244 | 0.170 |
Why?
|
| Fanconi Anemia | 1 | 2021 | 319 | 0.170 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2019 | 170 | 0.170 |
Why?
|
| S Phase | 1 | 2000 | 423 | 0.160 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2018 | 108 | 0.160 |
Why?
|
| Epistasis, Genetic | 2 | 2021 | 365 | 0.160 |
Why?
|
| G1 Phase | 1 | 2000 | 415 | 0.160 |
Why?
|
| Receptors, CXCR | 1 | 2018 | 52 | 0.160 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 424 | 0.160 |
Why?
|
| Lung Neoplasms | 7 | 2023 | 13019 | 0.160 |
Why?
|
| Hemangioma | 1 | 2003 | 737 | 0.160 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2018 | 109 | 0.160 |
Why?
|
| Kidney Calculi | 1 | 2023 | 465 | 0.160 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 3691 | 0.160 |
Why?
|
| Minority Health | 1 | 2019 | 86 | 0.160 |
Why?
|
| Antigens, Neoplasm | 2 | 2017 | 1983 | 0.160 |
Why?
|
| Cell Line, Tumor | 10 | 2019 | 16665 | 0.160 |
Why?
|
| Penile Diseases | 1 | 1998 | 46 | 0.160 |
Why?
|
| Pelvis | 3 | 2019 | 730 | 0.160 |
Why?
|
| Propensity Score | 7 | 2020 | 1771 | 0.150 |
Why?
|
| Guideline Adherence | 2 | 2019 | 2266 | 0.150 |
Why?
|
| Quality Improvement | 8 | 2016 | 3738 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 3014 | 0.150 |
Why?
|
| Hyperinsulinism | 1 | 2021 | 415 | 0.150 |
Why?
|
| Marital Status | 1 | 2019 | 437 | 0.150 |
Why?
|
| Genetic Markers | 4 | 2018 | 2633 | 0.150 |
Why?
|
| Acetates | 2 | 2013 | 312 | 0.150 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 6259 | 0.150 |
Why?
|
| Travel | 1 | 2023 | 788 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2021 | 627 | 0.150 |
Why?
|
| Down-Regulation | 3 | 2017 | 3001 | 0.140 |
Why?
|
| Retinal Dehydrogenase | 1 | 2016 | 74 | 0.140 |
Why?
|
| BRCA1 Protein | 3 | 2023 | 1145 | 0.140 |
Why?
|
| Quality of Health Care | 4 | 2020 | 4369 | 0.140 |
Why?
|
| Testicular Hydrocele | 1 | 2016 | 28 | 0.140 |
Why?
|
| Cryosurgery | 3 | 2006 | 453 | 0.140 |
Why?
|
| Cost of Illness | 5 | 2023 | 1852 | 0.140 |
Why?
|
| Patient Care | 1 | 2022 | 639 | 0.140 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2016 | 23 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2024 | 35342 | 0.140 |
Why?
|
| DNA Primers | 3 | 2006 | 2892 | 0.140 |
Why?
|
| Bone Neoplasms | 4 | 2014 | 2522 | 0.140 |
Why?
|
| Gene Deletion | 1 | 2004 | 2751 | 0.140 |
Why?
|
| Receptors, Immunologic | 2 | 2020 | 1423 | 0.140 |
Why?
|
| Carcinoma, Papillary | 1 | 2021 | 781 | 0.140 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2016 | 142 | 0.140 |
Why?
|
| Pain Perception | 1 | 2017 | 190 | 0.140 |
Why?
|
| Somatomedins | 1 | 2016 | 192 | 0.140 |
Why?
|
| BRCA2 Protein | 2 | 2022 | 790 | 0.130 |
Why?
|
| Analgesics, Opioid | 3 | 2020 | 3667 | 0.130 |
Why?
|
| Hypoalbuminemia | 1 | 2016 | 87 | 0.130 |
Why?
|
| Sequence Deletion | 2 | 2008 | 1526 | 0.130 |
Why?
|
| Colorectal Neoplasms | 7 | 2020 | 6754 | 0.130 |
Why?
|
| Testosterone | 4 | 2022 | 2401 | 0.130 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 365 | 0.130 |
Why?
|
| Osteoporotic Fractures | 1 | 2020 | 403 | 0.130 |
Why?
|
| Dementia | 2 | 2019 | 2501 | 0.130 |
Why?
|
| Administration, Intravesical | 2 | 2012 | 91 | 0.130 |
Why?
|
| Internship and Residency | 4 | 2016 | 5774 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2022 | 1860 | 0.130 |
Why?
|
| Models, Genetic | 3 | 2020 | 3493 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 20086 | 0.130 |
Why?
|
| Kidney | 6 | 2023 | 7167 | 0.130 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 2236 | 0.130 |
Why?
|
| Missouri | 3 | 2018 | 116 | 0.130 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2016 | 216 | 0.130 |
Why?
|
| Urethral Stricture | 1 | 2015 | 51 | 0.130 |
Why?
|
| Pain, Postoperative | 3 | 2020 | 1638 | 0.130 |
Why?
|
| Carbon | 2 | 2013 | 686 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 1835 | 0.130 |
Why?
|
| Heart Atria | 1 | 2001 | 1348 | 0.120 |
Why?
|
| Acetaminophen | 1 | 2019 | 544 | 0.120 |
Why?
|
| Accidents | 1 | 2015 | 164 | 0.120 |
Why?
|
| Erythropoiesis | 1 | 2018 | 705 | 0.120 |
Why?
|
| Dioxygenases | 1 | 2016 | 316 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 4929 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2018 | 546 | 0.120 |
Why?
|
| Regression Analysis | 5 | 2020 | 6452 | 0.120 |
Why?
|
| Clinical Trials as Topic | 8 | 2020 | 7901 | 0.120 |
Why?
|
| Suicide | 2 | 2015 | 1475 | 0.120 |
Why?
|
| Sexual Maturation | 1 | 2016 | 265 | 0.120 |
Why?
|
| Urinary Bladder Diseases | 1 | 1995 | 166 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2022 | 9941 | 0.120 |
Why?
|
| Insurance Benefits | 1 | 2016 | 183 | 0.120 |
Why?
|
| Vegetables | 1 | 2020 | 1179 | 0.120 |
Why?
|
| Carboplatin | 1 | 2017 | 799 | 0.120 |
Why?
|
| Erythropoietin | 1 | 2018 | 724 | 0.120 |
Why?
|
| Statistics as Topic | 2 | 2018 | 2372 | 0.120 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2015 | 194 | 0.120 |
Why?
|
| Workplace | 1 | 2020 | 836 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2023 | 1309 | 0.120 |
Why?
|
| Minority Groups | 2 | 2019 | 1215 | 0.120 |
Why?
|
| Software | 2 | 2018 | 4434 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 2005 | 2145 | 0.110 |
Why?
|
| Preventive Health Services | 1 | 2018 | 575 | 0.110 |
Why?
|
| Linkage Disequilibrium | 5 | 2016 | 1995 | 0.110 |
Why?
|
| Ovarian Neoplasms | 4 | 2019 | 4823 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2014 | 438 | 0.110 |
Why?
|
| Sample Size | 2 | 2020 | 844 | 0.110 |
Why?
|
| Urolithiasis | 1 | 2015 | 131 | 0.110 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2014 | 83 | 0.110 |
Why?
|
| Anticoagulants | 2 | 2019 | 4595 | 0.110 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1071 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2022 | 839 | 0.110 |
Why?
|
| Palliative Care | 3 | 2021 | 3478 | 0.110 |
Why?
|
| Capillaries | 1 | 2016 | 774 | 0.110 |
Why?
|
| Decision Support Techniques | 2 | 2014 | 1952 | 0.110 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 3510 | 0.110 |
Why?
|
| Mortality | 3 | 2020 | 2857 | 0.110 |
Why?
|
| Ureteral Obstruction | 1 | 2015 | 293 | 0.110 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2016 | 546 | 0.110 |
Why?
|
| Genetic Association Studies | 3 | 2017 | 2699 | 0.110 |
Why?
|
| Protective Agents | 1 | 2014 | 156 | 0.110 |
Why?
|
| Muscle, Smooth | 1 | 2017 | 933 | 0.110 |
Why?
|
| Intestinal Obstruction | 1 | 2016 | 424 | 0.110 |
Why?
|
| Nuclear Proteins | 3 | 2018 | 5851 | 0.110 |
Why?
|
| Young Adult | 16 | 2021 | 56350 | 0.110 |
Why?
|
| Cell Proliferation | 6 | 2018 | 10472 | 0.110 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2014 | 181 | 0.110 |
Why?
|
| Anemia | 1 | 2022 | 1499 | 0.110 |
Why?
|
| Forecasting | 3 | 2017 | 2948 | 0.110 |
Why?
|
| Aftercare | 1 | 2018 | 860 | 0.110 |
Why?
|
| Puerperal Disorders | 1 | 1995 | 275 | 0.100 |
Why?
|
| Reoperation | 2 | 2019 | 4200 | 0.100 |
Why?
|
| Metabolomics | 1 | 2020 | 1467 | 0.100 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 694 | 0.100 |
Why?
|
| Coffee | 1 | 2016 | 578 | 0.100 |
Why?
|
| Organ Size | 2 | 2007 | 2253 | 0.100 |
Why?
|
| Age of Onset | 3 | 2018 | 3266 | 0.100 |
Why?
|
| Urinary Tract Infections | 2 | 2015 | 786 | 0.100 |
Why?
|
| Metabolome | 1 | 2018 | 881 | 0.100 |
Why?
|
| Warfarin | 2 | 1997 | 1493 | 0.100 |
Why?
|
| Counseling | 1 | 2020 | 1521 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2023 | 5163 | 0.100 |
Why?
|
| Hospital Charges | 1 | 2013 | 362 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 638 | 0.100 |
Why?
|
| Piperidines | 1 | 2020 | 1602 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 403 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2003 | 322 | 0.100 |
Why?
|
| Penile Erection | 1 | 2011 | 97 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2023 | 2068 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2023 | 1794 | 0.100 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 2304 | 0.100 |
Why?
|
| Inpatients | 2 | 2013 | 2495 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 647 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2004 | 4282 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2002 | 3020 | 0.100 |
Why?
|
| DNA Damage | 1 | 2021 | 2423 | 0.100 |
Why?
|
| Transplantation, Heterologous | 3 | 2004 | 2382 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 1820 | 0.100 |
Why?
|
| Ischemia | 1 | 2020 | 1911 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2020 | 1581 | 0.090 |
Why?
|
| Necrosis | 2 | 2010 | 1643 | 0.090 |
Why?
|
| Angina Pectoris | 1 | 2015 | 977 | 0.090 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 401 | 0.090 |
Why?
|
| Double-Blind Method | 4 | 2021 | 12017 | 0.090 |
Why?
|
| Patient Discharge | 2 | 2023 | 3300 | 0.090 |
Why?
|
| Intestine, Small | 1 | 2016 | 1243 | 0.090 |
Why?
|
| Alleles | 7 | 2016 | 6931 | 0.090 |
Why?
|
| Spinal Fusion | 1 | 2019 | 1234 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 2502 | 0.090 |
Why?
|
| Adolescent | 16 | 2020 | 85649 | 0.090 |
Why?
|
| Eating | 1 | 2016 | 1535 | 0.090 |
Why?
|
| Societies, Medical | 4 | 2020 | 3740 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 2 | 2020 | 4465 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2014 | 2615 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 1581 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 1195 | 0.090 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 24913 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 2274 | 0.090 |
Why?
|
| Mice, SCID | 3 | 2018 | 2715 | 0.080 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2009 | 61 | 0.080 |
Why?
|
| Europe | 4 | 2021 | 3339 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2023 | 3861 | 0.080 |
Why?
|
| Steroid Hydroxylases | 1 | 2009 | 96 | 0.080 |
Why?
|
| Delayed-Action Preparations | 1 | 2012 | 965 | 0.080 |
Why?
|
| Body Height | 1 | 2015 | 1574 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2014 | 968 | 0.080 |
Why?
|
| Lymph Nodes | 4 | 2017 | 3465 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 3915 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 4 | 2003 | 6171 | 0.080 |
Why?
|
| Random Allocation | 3 | 2018 | 2425 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 2002 | 6313 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 2542 | 0.080 |
Why?
|
| Learning Curve | 1 | 2010 | 200 | 0.080 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 440 | 0.080 |
Why?
|
| Obesity | 2 | 2015 | 12705 | 0.080 |
Why?
|
| Coronary Artery Bypass | 1 | 1998 | 2281 | 0.080 |
Why?
|
| Surgical Wound Infection | 2 | 2015 | 1538 | 0.080 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2009 | 143 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2019 | 1461 | 0.080 |
Why?
|
| Calcifediol | 1 | 2009 | 166 | 0.080 |
Why?
|
| beta Catenin | 1 | 2013 | 1058 | 0.080 |
Why?
|
| RNA, Small Nucleolar | 1 | 2008 | 30 | 0.080 |
Why?
|
| Models, Statistical | 2 | 2021 | 5100 | 0.080 |
Why?
|
| Telomerase | 1 | 2013 | 729 | 0.080 |
Why?
|
| Phenotype | 3 | 2019 | 16331 | 0.080 |
Why?
|
| Health Status | 3 | 2018 | 4030 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2019 | 1457 | 0.080 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2007 | 21 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2015 | 12695 | 0.080 |
Why?
|
| Hospice Care | 1 | 2015 | 671 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 1618 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 2 | 2016 | 1831 | 0.080 |
Why?
|
| Ablation Techniques | 2 | 2020 | 249 | 0.080 |
Why?
|
| Calcitriol | 1 | 2009 | 298 | 0.080 |
Why?
|
| Genomics | 2 | 2021 | 5692 | 0.070 |
Why?
|
| RNA | 1 | 2017 | 2747 | 0.070 |
Why?
|
| Patient Admission | 1 | 2015 | 1380 | 0.070 |
Why?
|
| Animals | 15 | 2021 | 168561 | 0.070 |
Why?
|
| Molecular Sequence Annotation | 2 | 2021 | 527 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 950 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 3 | 2021 | 4801 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2009 | 2245 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 380 | 0.070 |
Why?
|
| Self Report | 4 | 2021 | 3548 | 0.070 |
Why?
|
| Ureter | 2 | 2015 | 374 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 7276 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2021 | 546 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 3 | 2016 | 1342 | 0.070 |
Why?
|
| Universities | 1 | 2011 | 953 | 0.070 |
Why?
|
| Cystoscopy | 2 | 2015 | 134 | 0.070 |
Why?
|
| Binding Sites | 1 | 2015 | 6115 | 0.070 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2006 | 54 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2018 | 13029 | 0.070 |
Why?
|
| DNA | 2 | 2016 | 7289 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 9410 | 0.070 |
Why?
|
| Estramustine | 1 | 2005 | 35 | 0.070 |
Why?
|
| Sensitivity and Specificity | 5 | 2013 | 14720 | 0.070 |
Why?
|
| Consensus | 3 | 2020 | 2935 | 0.070 |
Why?
|
| Wound Healing | 1 | 2016 | 2781 | 0.070 |
Why?
|
| Mitoxantrone | 1 | 2005 | 149 | 0.060 |
Why?
|
| Nephrons | 1 | 2006 | 220 | 0.060 |
Why?
|
| Tosyl Compounds | 1 | 2005 | 110 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 358 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 2712 | 0.060 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2016 | 199 | 0.060 |
Why?
|
| Mutation | 5 | 2016 | 29717 | 0.060 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 1288 | 0.060 |
Why?
|
| Lipids | 1 | 2016 | 3302 | 0.060 |
Why?
|
| Mice | 10 | 2020 | 81045 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2020 | 1839 | 0.060 |
Why?
|
| Quantitative Trait Loci | 3 | 2018 | 2015 | 0.060 |
Why?
|
| Perioperative Period | 2 | 2016 | 256 | 0.060 |
Why?
|
| von Hippel-Lindau Disease | 2 | 1995 | 152 | 0.060 |
Why?
|
| Medically Uninsured | 2 | 2020 | 852 | 0.060 |
Why?
|
| Urinary Tract | 1 | 2007 | 308 | 0.060 |
Why?
|
| Overweight | 1 | 2015 | 2366 | 0.060 |
Why?
|
| Probability | 2 | 2023 | 2502 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 1436 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2021 | 2736 | 0.060 |
Why?
|
| Endoribonucleases | 1 | 2006 | 228 | 0.060 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2023 | 50 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 5304 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 3957 | 0.060 |
Why?
|
| Anxiety | 2 | 2017 | 4279 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2013 | 2107 | 0.060 |
Why?
|
| Cost Savings | 2 | 2019 | 925 | 0.060 |
Why?
|
| Laparoscopes | 1 | 2003 | 41 | 0.060 |
Why?
|
| Terminal Care | 1 | 2015 | 1688 | 0.060 |
Why?
|
| Recurrence | 3 | 2011 | 8333 | 0.060 |
Why?
|
| Rectum | 1 | 2008 | 903 | 0.060 |
Why?
|
| Telemedicine | 1 | 2020 | 2853 | 0.060 |
Why?
|
| Kidney Calices | 1 | 2023 | 26 | 0.060 |
Why?
|
| Patient Selection | 2 | 2012 | 4214 | 0.060 |
Why?
|
| Stem Cells | 1 | 2016 | 3563 | 0.060 |
Why?
|
| Longitudinal Studies | 5 | 2018 | 13921 | 0.060 |
Why?
|
| Ureteroscopes | 1 | 2023 | 23 | 0.060 |
Why?
|
| Decision Making | 1 | 2017 | 3869 | 0.060 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 974 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2017 | 4231 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 2283 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 3639 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2009 | 2013 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5171 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 335 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 2749 | 0.050 |
Why?
|
| Ribonuclease H | 1 | 2022 | 45 | 0.050 |
Why?
|
| Hemostatic Techniques | 1 | 2003 | 116 | 0.050 |
Why?
|
| Anilides | 1 | 2005 | 404 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5611 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2015 | 2789 | 0.050 |
Why?
|
| Hemostasis, Surgical | 1 | 2002 | 128 | 0.050 |
Why?
|
| Electrocoagulation | 1 | 2002 | 158 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 363 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4751 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2003 | 571 | 0.050 |
Why?
|
| Ureteroscopy | 1 | 2023 | 142 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2012 | 5978 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2013 | 2896 | 0.050 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2022 | 97 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2021 | 8297 | 0.050 |
Why?
|
| Depression | 2 | 2019 | 7733 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2002 | 318 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2014 | 3748 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 2 | 2017 | 1661 | 0.050 |
Why?
|
| Melanoma | 1 | 2019 | 5462 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 19862 | 0.050 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 7770 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2006 | 1184 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2017 | 4551 | 0.050 |
Why?
|
| Population Control | 1 | 2020 | 20 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3557 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 4029 | 0.050 |
Why?
|
| Sepsis | 1 | 2015 | 2589 | 0.050 |
Why?
|
| Algorithms | 4 | 2018 | 13853 | 0.050 |
Why?
|
| Life Expectancy | 2 | 2019 | 1183 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2014 | 3328 | 0.050 |
Why?
|
| Costs and Cost Analysis | 2 | 2017 | 1679 | 0.050 |
Why?
|
| Diaphragm | 1 | 2002 | 347 | 0.050 |
Why?
|
| American Cancer Society | 1 | 2019 | 61 | 0.050 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 2195 | 0.050 |
Why?
|
| Hospitals, Teaching | 2 | 2017 | 1179 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 2410 | 0.050 |
Why?
|
| Morbidity | 2 | 2017 | 1767 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2023 | 5062 | 0.050 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 3 | 1997 | 290 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 1144 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2005 | 688 | 0.040 |
Why?
|
| Contig Mapping | 1 | 1999 | 54 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2018 | 3770 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 289 | 0.040 |
Why?
|
| Base Sequence | 3 | 2008 | 12797 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2011 | 3584 | 0.040 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1999 | 170 | 0.040 |
Why?
|
| Urinary Calculi | 1 | 1999 | 91 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2023 | 454 | 0.040 |
Why?
|
| Transfection | 2 | 2018 | 5892 | 0.040 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2018 | 26 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2018 | 1589 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2018 | 95 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 7153 | 0.040 |
Why?
|
| Histological Techniques | 1 | 2019 | 198 | 0.040 |
Why?
|
| Hospital Mortality | 3 | 2019 | 5310 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 163 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 3611 | 0.040 |
Why?
|
| Acid Phosphatase | 1 | 2018 | 141 | 0.040 |
Why?
|
| Pneumothorax | 1 | 2002 | 379 | 0.040 |
Why?
|
| Colon | 3 | 2021 | 1773 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 1998 | 803 | 0.040 |
Why?
|
| Anisotropy | 1 | 2021 | 1265 | 0.040 |
Why?
|
| Defoliants, Chemical | 1 | 2017 | 6 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2018 | 352 | 0.040 |
Why?
|
| Education, Medical, Continuing | 1 | 2003 | 839 | 0.040 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 18006 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2002 | 1062 | 0.040 |
Why?
|
| Ribonuclease III | 1 | 2020 | 275 | 0.040 |
Why?
|
| Prevalence | 2 | 2016 | 15194 | 0.040 |
Why?
|
| Prescriptions | 1 | 2020 | 387 | 0.040 |
Why?
|
| Ribs | 1 | 1999 | 250 | 0.040 |
Why?
|
| Apoptosis | 2 | 2013 | 9715 | 0.040 |
Why?
|
| Matrix Metalloproteinase 16 | 1 | 2017 | 4 | 0.040 |
Why?
|
| Blood Loss, Surgical | 3 | 2010 | 656 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 553 | 0.040 |
Why?
|
| Vietnam Conflict | 1 | 2017 | 99 | 0.040 |
Why?
|
| Interferons | 1 | 2021 | 704 | 0.040 |
Why?
|
| Survivors | 2 | 2023 | 2286 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 375 | 0.040 |
Why?
|
| Workflow | 1 | 2021 | 846 | 0.040 |
Why?
|
| Phthalazines | 1 | 2019 | 361 | 0.040 |
Why?
|
| Signal Transduction | 5 | 2019 | 23387 | 0.040 |
Why?
|
| Veterans | 3 | 2017 | 2513 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 1998 | 2940 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 351 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 617 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2000 | 670 | 0.030 |
Why?
|
| Histones | 2 | 2017 | 2597 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2017 | 215 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2000 | 701 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 808 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 4438 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 6483 | 0.030 |
Why?
|
| Ferritins | 1 | 2018 | 590 | 0.030 |
Why?
|
| Cooperative Behavior | 2 | 2013 | 1503 | 0.030 |
Why?
|
| Transcription Factors | 1 | 1995 | 12164 | 0.030 |
Why?
|
| Radiation Injuries | 2 | 2014 | 1178 | 0.030 |
Why?
|
| Microvessels | 1 | 2020 | 544 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 3391 | 0.030 |
Why?
|
| Cost Sharing | 1 | 2019 | 407 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2017 | 563 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 494 | 0.030 |
Why?
|
| Vitamin D | 1 | 2009 | 3211 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2018 | 2011 | 0.030 |
Why?
|
| Teratoma | 1 | 1998 | 387 | 0.030 |
Why?
|
| R-SNARE Proteins | 1 | 2015 | 75 | 0.030 |
Why?
|
| Urinalysis | 1 | 2017 | 369 | 0.030 |
Why?
|
| DNA Replication | 1 | 2022 | 1397 | 0.030 |
Why?
|
| Phospholipids | 1 | 2018 | 781 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2001 | 1538 | 0.030 |
Why?
|
| Income | 1 | 2024 | 1904 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2014 | 6365 | 0.030 |
Why?
|
| Atlases as Topic | 1 | 2016 | 237 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 902 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 1998 | 2085 | 0.030 |
Why?
|
| Gene Expression | 2 | 2018 | 7790 | 0.030 |
Why?
|
| Physicians | 1 | 2013 | 4554 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 1622 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 657 | 0.030 |
Why?
|
| Language | 1 | 2024 | 1458 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 3920 | 0.030 |
Why?
|
| Renal Artery | 1 | 2016 | 398 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 132 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 1995 | 354 | 0.030 |
Why?
|
| Laparotomy | 1 | 2016 | 474 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2021 | 1385 | 0.030 |
Why?
|
| Direct Service Costs | 1 | 2014 | 62 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 349 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2019 | 848 | 0.030 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2014 | 57 | 0.030 |
Why?
|
| Ohio | 1 | 2014 | 337 | 0.030 |
Why?
|
| Peritoneum | 1 | 1995 | 226 | 0.030 |
Why?
|
| Patients | 1 | 2020 | 892 | 0.030 |
Why?
|
| Endothelium | 1 | 2016 | 778 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 5385 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 544 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2017 | 585 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 11690 | 0.030 |
Why?
|
| Demography | 1 | 2018 | 1650 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2006 | 5095 | 0.030 |
Why?
|
| Bandages | 1 | 1995 | 267 | 0.030 |
Why?
|
| Pandemics | 2 | 2023 | 8328 | 0.030 |
Why?
|
| Sex Factors | 2 | 2019 | 10392 | 0.030 |
Why?
|
| Dextrans | 1 | 1995 | 592 | 0.030 |
Why?
|
| Perineum | 1 | 2014 | 211 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 1085 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 3760 | 0.030 |
Why?
|
| Urethra | 1 | 2015 | 408 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2016 | 730 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 508 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2016 | 544 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 240 | 0.030 |
Why?
|
| Puberty | 1 | 2016 | 489 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 783 | 0.030 |
Why?
|
| Digital Rectal Examination | 1 | 2012 | 42 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 1341 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 2505 | 0.030 |
Why?
|
| Vinblastine | 1 | 2014 | 490 | 0.030 |
Why?
|
| Hematocrit | 1 | 2014 | 636 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2019 | 2451 | 0.030 |
Why?
|
| Haplotypes | 1 | 2018 | 2781 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 1653 | 0.030 |
Why?
|
| Exosomes | 1 | 2016 | 412 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 281 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2013 | 538 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 726 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2014 | 778 | 0.020 |
Why?
|
| Appendectomy | 1 | 2014 | 400 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 2123 | 0.020 |
Why?
|
| Luciferases | 1 | 2013 | 733 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2016 | 2003 | 0.020 |
Why?
|
| Endonucleases | 1 | 2014 | 381 | 0.020 |
Why?
|
| Asia | 1 | 2013 | 607 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2019 | 1365 | 0.020 |
Why?
|
| International Cooperation | 1 | 2017 | 1421 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2008 | 18112 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2014 | 836 | 0.020 |
Why?
|
| Office Visits | 1 | 2015 | 598 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 1636 | 0.020 |
Why?
|
| Washington | 1 | 2011 | 313 | 0.020 |
Why?
|
| Proteins | 2 | 1997 | 6096 | 0.020 |
Why?
|
| Creatinine | 1 | 2016 | 1916 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2014 | 674 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2018 | 997 | 0.020 |
Why?
|
| Triglycerides | 1 | 2018 | 2450 | 0.020 |
Why?
|
| Australia | 1 | 2014 | 1167 | 0.020 |
Why?
|
| Life Style | 1 | 2022 | 3824 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 2217 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2018 | 2303 | 0.020 |
Why?
|
| Point Mutation | 1 | 1995 | 1624 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 740 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 3504 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 2876 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 1337 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2020 | 2924 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 1782 | 0.020 |
Why?
|
| Cholesterol | 1 | 2018 | 2895 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15108 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2000 | 2948 | 0.020 |
Why?
|
| Social Support | 1 | 2019 | 2117 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1997 | 1379 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2014 | 725 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 2414 | 0.020 |
Why?
|
| Epidemiologic Research Design | 1 | 2013 | 367 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2015 | 1533 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2013 | 780 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 1167 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2017 | 2964 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2019 | 3418 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2018 | 1575 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2018 | 4211 | 0.020 |
Why?
|
| Piperazines | 1 | 2019 | 2488 | 0.020 |
Why?
|
| RNA Interference | 1 | 2017 | 2890 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 11363 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1675 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 1181 | 0.020 |
Why?
|
| ROC Curve | 1 | 2016 | 3528 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2015 | 1525 | 0.020 |
Why?
|
| Health Surveys | 1 | 2018 | 4030 | 0.020 |
Why?
|
| Military Personnel | 1 | 2017 | 1132 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2019 | 1643 | 0.020 |
Why?
|
| Environmental Pollutants | 1 | 2017 | 1180 | 0.020 |
Why?
|
| Cisplatin | 1 | 2014 | 1637 | 0.020 |
Why?
|
| Mammography | 1 | 2019 | 2474 | 0.020 |
Why?
|
| Heparin | 1 | 1995 | 1636 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2015 | 2713 | 0.020 |
Why?
|
| Models, Economic | 1 | 2012 | 713 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1707 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 2215 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2015 | 974 | 0.020 |
Why?
|
| Methotrexate | 1 | 2014 | 1720 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2012 | 650 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2015 | 2739 | 0.020 |
Why?
|
| Social Class | 1 | 2016 | 1995 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2723 | 0.020 |
Why?
|
| Urination Disorders | 1 | 2008 | 241 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 6474 | 0.020 |
Why?
|
| Dissection | 1 | 2008 | 294 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 1995 | 13814 | 0.020 |
Why?
|
| Computational Biology | 1 | 2018 | 3518 | 0.020 |
Why?
|
| Models, Animal | 2 | 2003 | 2170 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 5872 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 1364 | 0.020 |
Why?
|
| Adiposity | 1 | 2015 | 1806 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 5519 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5180 | 0.020 |
Why?
|
| Spouses | 1 | 2008 | 284 | 0.020 |
Why?
|
| Medical Records | 1 | 2011 | 1413 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2016 | 2616 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2018 | 6191 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2008 | 642 | 0.020 |
Why?
|
| Cause of Death | 1 | 2015 | 3571 | 0.020 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 1204 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2020 | 14554 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2016 | 3461 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 6608 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2015 | 25575 | 0.010 |
Why?
|
| Japan | 1 | 2007 | 1360 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 2167 | 0.010 |
Why?
|
| Aspirin | 1 | 1995 | 3278 | 0.010 |
Why?
|
| Homozygote | 1 | 2008 | 1777 | 0.010 |
Why?
|
| Intestinal Diseases | 1 | 2008 | 531 | 0.010 |
Why?
|
| Radiography | 1 | 2014 | 7010 | 0.010 |
Why?
|
| Swine | 2 | 2003 | 5934 | 0.010 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2002 | 40 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 10943 | 0.010 |
Why?
|
| Critical Care | 1 | 2015 | 2640 | 0.010 |
Why?
|
| Lung | 1 | 2021 | 9826 | 0.010 |
Why?
|
| Internationality | 1 | 2007 | 1002 | 0.010 |
Why?
|
| Infant | 2 | 2015 | 35070 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 21821 | 0.010 |
Why?
|
| Cytoplasm | 2 | 1997 | 1539 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 5867 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2015 | 40955 | 0.010 |
Why?
|
| Contrast Media | 1 | 2014 | 5295 | 0.010 |
Why?
|
| Inflammation | 1 | 2021 | 10578 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 9735 | 0.010 |
Why?
|
| Mental Health | 1 | 2014 | 2997 | 0.010 |
Why?
|
| Surgical Instruments | 1 | 2002 | 394 | 0.010 |
Why?
|
| Models, Anatomic | 1 | 2003 | 690 | 0.010 |
Why?
|
| Ileum | 1 | 2001 | 565 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2019 | 6587 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 10163 | 0.010 |
Why?
|
| Calcium Oxalate | 1 | 1999 | 74 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2008 | 2050 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2009 | 2921 | 0.010 |
Why?
|
| Pregnancy | 1 | 2019 | 29087 | 0.010 |
Why?
|
| Linear Models | 1 | 2008 | 5948 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2002 | 1141 | 0.010 |
Why?
|
| Genome, Human | 1 | 2010 | 4420 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2013 | 3306 | 0.010 |
Why?
|
| Research Design | 1 | 2013 | 5979 | 0.010 |
Why?
|
| Child | 2 | 2015 | 77478 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1995 | 263 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 1188 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 15530 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 1998 | 421 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2010 | 4681 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1995 | 402 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1998 | 334 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1995 | 1581 | 0.010 |
Why?
|
| Testis | 1 | 1997 | 800 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2003 | 2658 | 0.010 |
Why?
|
| Uterus | 1 | 1997 | 710 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1997 | 2335 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 1680 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1995 | 2126 | 0.000 |
Why?
|
| Liver | 1 | 1997 | 7470 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1995 | 7721 | 0.000 |
Why?
|